Blockade of 146b-5p promotes inflammation in atherosclerosis-associated foam cell formation by targeting TRAF6

Nan Lin1,2, Yi An3

  • 1Department of Clinical Medicine, Medical College, Qingdao University, Qingdao, Shandong 266021, P.R. China.

Insights

Inhibition of miR-146b-5p worsens atherosclerosis by promoting inflammation and lipid uptake in foam cells. This microRNA targets TRAF6, a key player in the inflammatory NF-κB pathway.

Area of Science:

  • Cardiovascular Biology
  • Molecular Biology
  • Inflammation Research

Background:

  • Atherosclerosis (AS) involves chronic inflammation linked to lipid accumulation.
  • MicroRNAs (miRs) play significant roles in inflammatory processes.
  • The specific role of miR-146b-5p in AS remains unclear.

Purpose of the Study:

  • To investigate the role of miR-146b-5p in atherosclerosis.
  • To elucidate the underlying molecular mechanisms of miR-146b-5p in AS.
  • To determine the relationship between miR-146b-5p, foam cell formation, and inflammation.

Main Methods:

  • Quantification of miR-146b-5p levels in AS patient specimens and foam cells using reverse-transcription quantitative PCR.
  • Experimental inhibition of miR-146b-5p in cellular models.
  • Investigation of miR-146b-5p's direct targeting of TRAF6 and its impact on the NF-κB pathway.

Main Results:

  • miR-146b-5p expression is elevated in AS lesions and foam cells.
  • Oxidized low-density lipoprotein treatment increases miR-146b-5p levels in differentiating macrophages.
  • miR-146b-5p directly targets TRAF6, a component of the NF-κB signaling pathway.
  • Inhibition of miR-146b-5p exacerbates inflammation and lipid uptake in foam cell formation.

Conclusions:

  • miR-146b-5p plays a detrimental role in atherosclerosis-associated foam cell formation.
  • Inhibition of miR-146b-5p promotes chronic inflammation and lipid accumulation.
  • Targeting TRAF6 by miR-146b-5p is a key mechanism in its pro-inflammatory role in AS.

Related Concept Videos

Inflammation01:38

Inflammation

Overview
62.6K
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
1.3K
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
571
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.6K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
460